STOCKS TELEGRAPH

Tag: Jaguar Health Stock

  • Jaguar Health (JAGX) Stock Regains Ground In After-Hour Session

    Jaguar Health (JAGX) Stock Regains Ground In After-Hour Session

    After-hours trading on Wednesday saw a big recovery in Jaguar Health, Inc. (NASDAQ: JAGX) shares, which rose 8.33% to $3.01. The shares ended the trading day at $2.78, somewhat offsetting the company’s previous 14.06% regular-session drop. The recovery followed a virtual presentation at the Emerging Growth Conference by Lisa Conte, the founder and CEO of Jaguar Health, outlining the company’s recent accomplishments and future objectives.

    Advancing Canalevia-CA1 in Veterinary Medicine

    Recently, a field research was started by Jaguar Health’s Jaguar Animal Health subsidiary for Canalevia-CA1, an FDA-conditionally authorized medicine for canine chemotherapy-induced diarrhea (CID). This prospective, randomized, open-label clinical research, which involves dogs receiving chemotherapy across the United States, has seen the establishment of the company’s first study site. The research compares the results of the treatment and control groups in order to gather empirical data in favor of complete FDA clearance.

    Enhanced Indications and Strategic Objectives

    Securing complete FDA clearance for the CID indication and expanding its usage to treat general, non-infectious diarrhea in dogs are the two primary goals Jaguar Health is pursuing with Canalevia-CA1 (crofelemer delayed-release tablets). Discussions are underway with potential partners to support the development and global commercialization of crofelemer for this broader indication.

    This strategic expansion reflects the company’s recognition of a significant unmet need in veterinary medicine. Jaguar Health estimates approximately six million annual cases of acute and chronic canine diarrhea are seen by U.S. veterinarians, marking a considerable market opportunity.

    Regulatory Progress and Development Focus

    Jaguar Health has opened a new Investigational New Animal Drug (INAD) filing with the FDA’s Center for Veterinary Medicine to investigate the possibility of using crofelemer to treat dogs’ general, non-infectious diarrhea in order to assist these efforts. As a major driver of its continuous business growth activities, the firm has determined that establishing a strategic alliance for this program is a top goal for 2025.

  • Jaguar Health (JAGX) Stock Rebounds After Announcing Cancer Care Expansion

    Jaguar Health (JAGX) Stock Rebounds After Announcing Cancer Care Expansion

    Last Friday during the after-market session, there was a noticeable increase in the shares of Jaguar Health, Inc. (NASDAQ: JAGX) following the announcement of a noteworthy commercial endeavor. After a normal session fall of -9.75% that left the shares at $4.63, the stock had a comeback of 6.914% after hours, finishing at $4.95.

    Increasing Business Activity

    Jaguar Health (JAGX) shared intention to expand its commercial operations in its main area of expertise, cancer supportive care. Part of that plan, JAGX will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, which runs from May 31 to June 4. During the event, JAGX-division Napo Pharmaceuticals will have Gelclair on display at a booth. Jaguar Health recently obtained the in-license to sell Gelclair, a prescription drug authorized by the FDA for treating oral mucositis. The commercial launch of Gelclair is scheduled to commence in the third quarter of 2024 by Jaguar Health.

    Addressing Cancer Patients Issues

    JAGX’s Gelclair is a barrier-forming protective gel that coats the oral mucosa to assist control and lessen pain. It is used to treat sores in the mouth brought on by a number of illnesses, including oral mucositis and stomatitis. Gelclair does not hurt or function as a numbing agent like other treatments.

    Oral mucositis has a substantial financial impact; extra expenses for each patient with head and neck cancer surpass $17,000. With its handy, user-friendly, and clinically proven approach, Gelclair delivers patients quick and durable pain relief that enhances their ability to swallow, eat, drink, speak, and sleep.  It also reduces the necessity for parenteral feeding and opiate analgesics.

    Expanding Focus On Cancer Supportive Care

    At the ASCO Annual Meeting, Jaguar Health will promote awareness among oncologists about Gelclair and the company’s growing commitment to cancer supportive care. This commitment is further underscored by Jaguar Health’s five-year dedication to studying the prevention of cancer therapy-related diarrhea through the phase 3 OnTarget trial. This trial focuses on over 24 targeted cancer agents that have an incidence of more than 50% diarrhea, with top-line results expected soon.

  • Is JAGX Stock Up Premarket For A Reason?

    During pre-market trading on Tuesday, Jaguar Health Inc. (JAGX) climbed 2.55% to $1.61. The Jaguar Health stock finished the last trading session down -4.85% at $1.57. The price range for JAGX stock was between $1.55 and $1.65. During the past 100 days, JAGX stock traded 3.33 million shares daily but the volume of 11.44 million shares traded in the last session was much higher than that. In the past five days, JAGX shares have gained 3.29%, but have lost -17.80% over a month. We can use recent developments to provide a deeper understanding of the company as JAGX stock rose despite no current news.

    What is the latest from JAGX?

    As a commercial stage pharmaceuticals company, Jaguar Health aims to develop plant-based, non-opiod, and sustainably-derived prescription medications that are safe and effective for people and animals with GI distress, especially chronic, debilitating diarrhea. JAGX’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of plants harvested from rainforest areas for use in gastrointestinal pharmaceuticals.

    As the only oral plant-based prescription medicine approved under FDA Botanical Guidance, the Mytesi product developed by JAGX provides symptomatic relief of noninfectious diarrhea associated with HIV/AIDS in adults on antiretroviral therapy. The Napo EU S.p.A. subsidiary of Napo Pharmaceuticals aims to expand access to crofelemer in Europe.

    For the third time, Jaguar Health’s annual shareholders’ meeting on May 13 has been adjourned due to a lack of quorum.

    • Hence, the adjourned meeting of JAGX will now be held on August 6, 2021.
    • JAGX will hold its annual meeting at its San Francisco office.
    • The record date used to determine which JAGX stockholders will be eligible for the Annual Meeting was April 12, 2021.
    • The proposals have been generally well received by JAGX stockholders.
    • A JAGX stockholder who does not intend to revoke or change his or her previously delivered proxy is not required to take any action.
    • During the annual meeting, JAGX encouraged its eligible stockholders who still have not voted their shares / provided voting instructions to their broker / other record holder to do so.
    • The company counted on their participation as to reach quorum, JAGX still needs to receive votes from 2.9% of its eligible common stockholders.

    How can JAGX shareholders vote?

    There are several voting options available to Jaguar Health (JAGX) shareholders. Shareholders of JAGX can vote by internet at http://www.voteproxy.com or by phoning 800-776-9437 24 hours a day or submitting a proxy card properly executed. The street name holders of JAGX stock have the option of voting via their broker. In the process of preparing the proposals for stockholders to vote on at the Annual Meeting, JAGX has not made any changes.

  • Jaguar Health (JAGX) Closes its M Promissory Notes, What’s Next for JAGX Stock?

    Jaguar Health (JAGX) Closes its $6M Promissory Notes, What’s Next for JAGX Stock?

    Jaguar Health has had swift growth in 2020 as the demand for its Mytesi continues to rise.

    The pharmaceutical firm has kicked off the new year in style. Jaguar Health (JAGX) stock soared over 265% in the first week of January. The early-year gains indicate that the penny stock has a long way to go in 2021. The bull run is directing towards a positive trajectory as we move ahead.

    Recently, the company announced that it has entered into a definitive agreement to sell its promissory notes worth $6 million to Streeterville Capital—investor. Also, there’s a notable development happening across its novel proprietary drug, Crofelemer. So, 2021 is going to be exciting for Jaguar Health’s stock.

    What’s Next?

    Jaguar Health is heading in the right direction. The company has been quite active recently. On Jan. 13, 2021, Jaguar announced the purchase agreement for the sale of its common stock shares to its institutional investors. Around 4,437,870 common stock shares were floated at a per-share price of $3.38 that would bring gross proceeds of almost $15 million.

    On the very same day, the company also announced a binding agreement of terms for $6 million backed by the sale of tropical disease priority review voucher. Jaguar’s subsidiary, Napo Pharmaceuticals intends to go for an incentive for the development of Napo’s lechlemer drug with the help of this priority review voucher.

    On Jan. 19, the company signed a definitive agreement to issue and sell its secured promissory note to Streeterville for a principal amount of $6 million. Jaguar reported that the sale of Note closed on Jan. 19, 2021.

    Following the promissory note sale, Streeterville has the right to 18% of the gross proceeds of the review voucher for lechlemer drug. Whereas, Jaguar can redeem the Note at a 12.5% premium after the 6-months—any time.

    Moreover, the company is working to obtain conditional marketing authorization in Europe for its novel proprietary drug, Crofelemer. The company wants to conduct the initial study on Crofelemer in a “long-hauler” COVID-19recovery patient population in Europe. Jaguar is looking to accelerate the development and commercialization of Crofelemer as it’s the need of the hour—once it obtains the regulatory approval.

    Jaguar Health has another strong product in the market that’s making a lot of revenue. Napo’s product, Mytesi® reported a net sale of almost $2.8 million in Q3 2020, an increase from $1 million in 2019.

    Conclusion

    Jaguar Health (JAGX) is well-position across different spaces and is making way for its new product, Crofelemer, in Europe. From a penny stock in 2020 to cross the $3 price mark this year, JAGX has shown serious promise. Investors are keeping an eye on the stock; it will be making moves this year. The average trading volume stands around 57.5 million, as we write this. So, some serious bulls are coming Jaguar’s way.

  • Jaguar Health (JAGX) Spikes Above 70% following the announcement of its Novel Proprietary Drug for ‘Long-Hauler’ COVID-19 Patients

    Jaguar Health (JAGX) Spikes Above 70% following the announcement of its Novel Proprietary Drug for ‘Long-Hauler’ COVID-19 Patients

    Jaguar Health has decided to develop and commercialize Crofelemer for the treatment of COVID-19 recovery patients suffering from long-term diarrhea. The study is planned to begin in Europe.

    Jaguar Health, Inc. (JAGX) stock is on a roll today after the company along with its wholly-owned subsidiary, Napo Pharmaceuticals announced that they are planning to develop and commercialize their novel proprietary drug, Crofelemer. This drug will be developed for the COVID-19 recovery patients that are suffering from inflammatory diarrhea or prophylaxis.

    JAGX stock is skyrocketing on the initiation update of Crofelemer. The stock opened the trading at $0.21 and is currently trading at $0.36 continuing to soar by almost 74%. The trading volume is high at 90 million compared to the average volume of 6.4 million, as we write this.

    Jaguar and Napo are planning to begin the study on a ‘long-hauler’ COVID-19 recovery patient population in Europe.The novel proprietary drug, Crofelemer, will indicate the symptomatic relief of inflammatory diarrhea that will be studied in the clinical testing.

    The increasing COVID-19 cases have brought worse things to people as coronavirus patients are suffering from different issues. One of the major symptoms for COVID-19 patients is long-term diarrhea or other gastrointestinal disfunctions.

    At the moment, the company is in talks with the Swiss Growth Forum on the potential merger of SPAC with an operational subsidiary of the Company. The subsidiary will be located in Europe that will have an exclusive license for developing and commercializing crofelemer and Mytesi®.

    Based on the initial discussions, the company has reported that the agreement will include an upfront cash license fee of almost $2 million to $10 million to Napo. The cash payment will also include approximately $20 million for funding the European operation. It will also include equity ownership of 30%-49.5% for Napo in the European subsidiary, post-acquisition by the SPAC.

    The agreement will also have other customary financial terms including transfer pricing and royalties upon the sale of crofelemer and Mytesi in Europe.

    The “long-hauler” project is specifically associated with COVID-19 patients who have symptoms which may include diarrhea, pain, constipation, brain fog, cardiovascular effects, fatigue, and arthritis. The study will be based on solving patient problems having these symptoms.

    Napo has already completed the intellectual property filings for the development of Crofelemer. With the indications of potential long-hauler project, the company is focused on IP protection.

    Jaguar and Napo have defined the endpoints for the study before they commercialize their product for COVID-19 patients. The primary endpoints include prophylaxis, gut biome restoration, and reduction in inflammatory gut markers and viral fecal shedding.